No Data
Anhui Anke Biotechnology (300009.SZ) plans to distribute 1 yuan for every 10 shares in the first three quarters, with the ex-rights and ex-dividend date on January 17.
Anhui Anke Biotechnology (300009.SZ) announced that it plans to distribute 1 share for every 10 shares to all Shareholders in the first three quarters of 2024...
5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Anhui Anke Biotechnology (Group) (SZSE:300009) Shareholders Over That Period
Anhui Anke Biotechnology (300009.SZ) plans to distribute 1 yuan for every 10 shares in profit allocation for the first three quarters.
Anhui Anke Biotechnology (300009.SZ) disclosed the profit distribution plan for the first three quarters of 2024, proposing to distribute to all shareholders...
Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Stock Is Going Strong: Is the Market Following Fundamentals?
Anhui Anke Biotechnology (300009.SZ): The application for new indications of human growth hormone injection has been accepted.
On November 25, Glonghui reported that anhui anke biotechnology (300009.SZ) announced that recently, anhui anke biotechnology engineering (group) co., ltd. received the administrative license document "Acceptance Notice" from the National Medical Products Administration. The company's supplemental application for the indication of human growth hormone injection for small for gestational age (SGA) was accepted, with acceptance number: CYSB2400303. The goal of human growth hormone treatment for SGA is to accelerate the completion of catch-up growth in early childhood linear growth and to sustain growth during late childhood development.
Anhui Anke Biotechnology (300009.SZ): The controlling shareholder, actual controller, and some directors and executives intend to reduce their shareholding in the company.
Glory Exchange reported on November 20th that anhui anke biotechnology (300009.SZ) announced that the actual controller, controlling shareholder, director, and senior manager Song Lihua, controlling shareholder, actual controller, and director Song Liming, as well as director and senior manager Zhao Hui plan to reduce their shareholding in the company. Song Lihua plans to reduce 12 million shares, accounting for 0.72% of the company's total share capital; Song Liming plans to reduce 4 million shares, accounting for 0.24% of the company's total share capital; Zhao Hui plans to reduce 0.2 million shares, accounting for 0.01% of the company's total share capital. The methods of reduction include centralized bidding and block trades, and the reduction period is fifteen days from the date of announcement.
Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) Looks Inexpensive But Perhaps Not Attractive Enough
